ArticleActa diabetologica2026
PDX-1 related diabetes: a case series of two families highlighting challenges in MODY diagnosis.
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PDX1-MODY is a rare, dominantly inherited form of monogenic diabetes resulting from pathogenic variants in the PDX1 (IPF1) gene. It typically presents with early-onset, non-ketotic hyperglycemia and variable insulin dependence. This report describes two unrelated families carrying confirmed PDX1 variants (c.313G > T [p.Glu105*] and c.492G > T [p.Glu164Asp]) that illustrate the clinical and genetic heterogeneity of PDX1-MODY. Comprehensive next-generation sequencing (NGS) including a 36-gene panel for monogenic diabetes confirmed the variants, which were classified according to ACMG/AMP 2015 guidelines as "pathogenic" (p.Glu105)* and "likely pathogenic" (p.Glu164Asp). Clinically, both pedigrees exhibited preserved C-peptide secretion over decades, absence of autoimmune markers, and progressive β-cell dysfunction, confirming the variable but characteristic phenotype of PDX1-MODY. These cases expand the mutational and phenotypic spectrum of PDX1-MODY and highlight the importance of considering monogenic diabetes in early-onset, antibody-negative cases.
Indexed as
Identifiers
41201616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.